Uniform Distribution in the Nail Plate - Penlac® Nail Lacquer
FOR U.S. RESIDENTS ONLY
Penlac® Nail Lacquer (ciclopirox) Topical Solution, 8%: Safe and on target
About Nail Fungus Treatment with Penlac® For People with Diabetes For Healthcare Professionals
Search













Uniform Distribution in the Nail Plate

The active ingredient in Penlac® is a proven antifungal

  • Ciclopirox demonstrates fungicidal and fungistatic activity in vitro[1,5-8]
  • Ciclopirox is effective against dermatophytes across multiple species[1,5-8]*

Penlac® delivers a high concentration of ciclopirox at the site of infection[4]

Adapted from Bohn and Kraemer.[4]

*Penlac® is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Trichophyton rubrum.[1]

Distribution of ciclopirox in nail layers over time[4]

  • In one study, ciclopirox was uniformly distributed in all layers of the nail after only 7 days of application[4]
  • After application times of 7 to 14 days, a high level of biological activity was demonstrated[4]

Adapted from Bohn and Kraemer.[4]

From studies involving healthy subjects, penetration of ciclopirox through the nails was investigated. Nail samples were obtained and ciclopirox concentrations in the nail were determined by microbiologic assay.

The clinical relevance of these findings is unknown.[4]


Penlac® is indicated in immunocompetent patients with mild to moderate onychomycosis without lunula involvement due to Trichophyton rubrum.
IMPORTANT SAFETY INFORMATION
Penlac®, part of a comprehensive management program, includes regular removal of the unattached, infected nail by a health care professional, especially for patients with diabetes. Clinical data regarding use of systemic antifungals and Penlac® is not available to support concomitant use. Penlac® is well-tolerated: treatment-related side effects were periungual erythema (5%) and nail disorders (2%).

Patients with insulin-dependent diabetes or those with diabetic neuropathy were not included in pivotal clinical trials with Penlac®.
For more information, please see Full Prescribing Information for Penlac®

Your privacy
Dermik Laboratories respects your interest in keeping your personal health information private. The information you provide below will be used only for the purpose of sending an email message to the recipient and will not be saved. For more information, see our Privacy Policy.

Your name:

Your email address:

Recipient's email address:






Processing...





Thank you!
Your email has been sent.